Real-time monitoring β-lactam/β-lactamase inhibitor (BL/BLI) mixture towards the bacteria porin pathway at single molecule level.


Journal

Analytical and bioanalytical chemistry
ISSN: 1618-2650
Titre abrégé: Anal Bioanal Chem
Pays: Germany
ID NLM: 101134327

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 15 11 2018
accepted: 28 01 2019
revised: 09 01 2019
pubmed: 3 3 2019
medline: 31 7 2019
entrez: 3 3 2019
Statut: ppublish

Résumé

Multidrug-resistant bacteria are a great concern and a problem that must be addressed. Extended-spectrum β-lactamases are a common defence mechanism of bacteria to make β-lactam (BL) antibiotics ineffective. β-Lactamase inhibitors (BLIs) are consequently designed and are often clinically prescribed with a BL antibiotic to hinder degradation. Current studies focusing on how BL antibiotics or BLIs interact solely with the bacterial outer membrane nanopores (porins) on reaching the periplasmic side using a nanopore-based sensing technique. In electrochemical studies, the bias voltage allows real-time monitoring of BL antibiotics, BLIs and their mixture through the porin pathway at the single-molecule level. Here we consider the most abundant membrane protein from Escherichia coli (i.e. OmpF), purify and reconstitute the membrane protein in an artificial lipid bilayer and then study its ex vivo electrochemical behaviour. We show the piperacillin/tazobactam mixture interacts with OmpF, whereas the substrate interacts under the maximum bandwidth. The power spectrum analysis of the ionic current trace demonstrates the ampicillin/sulbactram mixture requires more energy than ampicillin alone to pass through the porin pathway. Our results demonstrate that clinically relevant combinations (e.g. piperacillin/tazobactam and ampicillin/sulbactam) interact more strongly with OmpF than either the BL antibiotic or the BLI alone. We suggest a quick and relatively cheap screening method to test the ability of BL antibiotics/BLIs to cross the bacterial cellular membrane.

Identifiants

pubmed: 30824965
doi: 10.1007/s00216-019-01650-3
pii: 10.1007/s00216-019-01650-3
doi:

Substances chimiques

Enzyme Inhibitors 0
Porins 0
beta-Lactamase Inhibitors 0
beta-Lactams 0

Types de publication

Journal Article

Langues

eng

Pagination

4831-4837

Subventions

Organisme : Chen Guang Project
ID : 17CG27

Auteurs

Jiajun Wang (J)

School of Chemistry & Molecular Engineering, East China University of Science and Technology, Shanghai, 200237, China. jiajun.wang@ecust.edu.cn.
Department of Life Sciences and Chemistry, Jacobs University Bremen, 28759, Bremen, Germany. jiajun.wang@ecust.edu.cn.

Niels Fertig (N)

Nanion Technologies GmbH, 80339, Munich, Germany.

Yi-Lun Ying (YL)

School of Chemistry & Molecular Engineering, East China University of Science and Technology, Shanghai, 200237, China. yilunying@ecust.edu.cn.

Articles similaires

Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation
Biofilms Candida albicans Quorum Sensing Candida glabrata Menthol
Fucosyltransferases Drug Repositioning Molecular Docking Simulation Molecular Dynamics Simulation Humans

Naturally derived 3-aminoquinuclidine salts as new promising therapeutic agents.

Doris Crnčević, Alma Ramić, Andreja Radman Kastelic et al.
1.00
Humans Microbial Sensitivity Tests Anti-Bacterial Agents Biofilms Quinuclidines

Classifications MeSH